122 related articles for article (PubMed ID: 29132840)
1. d-Peptides as inhibitors of PR3-membrane interactions.
Maximova K; Venken T; Reuter N; Trylska J
Biochim Biophys Acta Biomembr; 2018 Feb; 1860(2):458-466. PubMed ID: 29132840
[TBL] [Abstract][Full Text] [Related]
2. Peptidomimetic inhibitors targeting the membrane-binding site of the neutrophil proteinase 3.
Maximova K; Reuter N; Trylska J
Biochim Biophys Acta Biomembr; 2019 Aug; 1861(8):1502-1509. PubMed ID: 31229588
[TBL] [Abstract][Full Text] [Related]
3. Computational prediction of the binding site of proteinase 3 to the plasma membrane.
Hajjar E; Mihajlovic M; Witko-Sarsat V; Lazaridis T; Reuter N
Proteins; 2008 Jun; 71(4):1655-69. PubMed ID: 18076025
[TBL] [Abstract][Full Text] [Related]
4. Proteinase 3 Is a Phosphatidylserine-binding Protein That Affects the Production and Function of Microvesicles.
Martin KR; Kantari-Mimoun C; Yin M; Pederzoli-Ribeil M; Angelot-Delettre F; Ceroi A; Grauffel C; Benhamou M; Reuter N; Saas P; Frachet P; Boulanger CM; Witko-Sarsat V
J Biol Chem; 2016 May; 291(20):10476-89. PubMed ID: 26961880
[TBL] [Abstract][Full Text] [Related]
5. How does proteinase 3 interact with lipid bilayers?
Broemstrup T; Reuter N
Phys Chem Chem Phys; 2010 Jul; 12(27):7487-96. PubMed ID: 20532386
[TBL] [Abstract][Full Text] [Related]
6. New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases.
Guarino C; Legowska M; Epinette C; Kellenberger C; Dallet-Choisy S; Sieńczyk M; Gabant G; Cadene M; Zoidakis J; Vlahou A; Wysocka M; Marchand-Adam S; Jenne DE; Lesner A; Gauthier F; Korkmaz B
J Biol Chem; 2014 Nov; 289(46):31777-31791. PubMed ID: 25288799
[TBL] [Abstract][Full Text] [Related]
7. Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3.
Budnjo A; Narawane S; Grauffel C; Schillinger AS; Fossen T; Reuter N; Haug BE
J Med Chem; 2014 Nov; 57(22):9396-408. PubMed ID: 25365140
[TBL] [Abstract][Full Text] [Related]
8. A selective reversible azapeptide inhibitor of human neutrophil proteinase 3 derived from a high affinity FRET substrate.
Epinette C; Croix C; Jaquillard L; Marchand-Adam S; Kellenberger C; Lalmanach G; Cadene M; Viaud-Massuard MC; Gauthier F; Korkmaz B
Biochem Pharmacol; 2012 Mar; 83(6):788-96. PubMed ID: 22209715
[TBL] [Abstract][Full Text] [Related]
9. Design and use of highly specific substrates of neutrophil elastase and proteinase 3.
Korkmaz B; Attucci S; Moreau T; Godat E; Juliano L; Gauthier F
Am J Respir Cell Mol Biol; 2004 Jun; 30(6):801-7. PubMed ID: 14693667
[TBL] [Abstract][Full Text] [Related]
10. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition.
Campbell EJ; Campbell MA; Owen CA
J Immunol; 2000 Sep; 165(6):3366-74. PubMed ID: 10975855
[TBL] [Abstract][Full Text] [Related]
11. The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction.
Choi M; Eulenberg C; Rolle S; von Kries JP; Luft FC; Kettritz R
Clin Exp Immunol; 2010 Aug; 161(2):389-96. PubMed ID: 20456416
[TBL] [Abstract][Full Text] [Related]
12. Human proteinase 3 (PR3) and its binding molecules: implications for inflammatory and PR3-related autoimmune responses.
Müller A; Voswinkel J; Gottschlich S; Csernok E
Ann N Y Acad Sci; 2007 Aug; 1109():84-92. PubMed ID: 17785293
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of the membrane insertion domain of proteinase 3, the Wegener's autoantigen, in RBL cells: implication for its pathogenic activity.
Kantari C; Millet A; Gabillet J; Hajjar E; Broemstrup T; Pluta P; Reuter N; Witko-Sarsat V
J Leukoc Biol; 2011 Nov; 90(5):941-50. PubMed ID: 21821719
[TBL] [Abstract][Full Text] [Related]
14. Human proteinase 3 resistance to inhibition extends to alpha-2 macroglobulin.
N'Guessan K; Grzywa R; Seren S; Gabant G; Juliano MA; Moniatte M; van Dorsselaer A; Bieth JG; Kellenberger C; Gauthier F; Wysocka M; Lesner A; Sienczyk M; Cadene M; Korkmaz B
FEBS J; 2020 Sep; 287(18):4068-4081. PubMed ID: 31995266
[TBL] [Abstract][Full Text] [Related]
15. Mapping of conformational epitopes on human proteinase 3, the autoantigen of Wegener's granulomatosis.
Kuhl A; Korkmaz B; Utecht B; Kniepert A; Schönermarck U; Specks U; Jenne DE
J Immunol; 2010 Jul; 185(1):387-99. PubMed ID: 20530264
[TBL] [Abstract][Full Text] [Related]
16. Membrane proteinase 3 and its interactions within microdomains of neutrophil membranes.
Fridlich R; David A; Aviram I
J Cell Biochem; 2006 Sep; 99(1):117-25. PubMed ID: 16598772
[TBL] [Abstract][Full Text] [Related]
17. Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener's granulomatosis.
Witko-Sarsat V; Reuter N; Mouthon L
Curr Opin Rheumatol; 2010 Jan; 22(1):1-7. PubMed ID: 19881350
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease.
Korkmaz B; Lesner A; Guarino C; Wysocka M; Kellenberger C; Watier H; Specks U; Gauthier F; Jenne DE
Pharmacol Rev; 2016 Jul; 68(3):603-30. PubMed ID: 27329045
[TBL] [Abstract][Full Text] [Related]
19. Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases.
Korkmaz B; Jenne DE; Gauthier F
Int Immunopharmacol; 2013 Dec; 17(4):1198-205. PubMed ID: 23886601
[TBL] [Abstract][Full Text] [Related]
20. Proteinase 3, the autoantigen in granulomatosis with polyangiitis, associates with calreticulin on apoptotic neutrophils, impairs macrophage phagocytosis, and promotes inflammation.
Gabillet J; Millet A; Pederzoli-Ribeil M; Tacnet-Delorme P; Guillevin L; Mouthon L; Frachet P; Witko-Sarsat V
J Immunol; 2012 Sep; 189(5):2574-83. PubMed ID: 22844112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
